Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


13.03.2017

1 AJR Am J Roentgenol
1 Am J Clin Pathol
1 BJU Int
2 BMC Cancer
1 Br J Cancer
1 Br J Radiol
1 Cancer
1 Cancer Lett
1 Clin Imaging
1 Eur Radiol
3 Eur Urol
1 Int J Oncol
1 Int J Radiat Oncol Biol Phys
1 Invest Radiol
1 J Natl Med Assoc
2 Lancet Oncol
1 N Engl J Med
1 Nat Rev Urol
1 Oncol Rep
1 Prog Urol
1 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. LIM CS, McInnes MD, Flood TA, Breau RH, et al
    Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
    AJR Am J Roentgenol. 2017 Mar 7:1-8. doi: 10.2214/AJR.16.16843.
    PubMed     Text format     Abstract available


    Am J Clin Pathol

  2. GOLDSTEIN J, Goyal R, Roland JT, Gellert LL, et al
    MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma: A Comparison With AMACR.
    Am J Clin Pathol. 2016;146:294-302.
    PubMed     Text format     Abstract available


    BJU Int

  3. KANTHABALAN A, Peters M, Van Vulpen M, McCartan N, et al
    Focal Salvage HIFU in radiorecurrent prostate cancer.
    BJU Int. 2017 Mar 4. doi: 10.1111/bju.13831.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. DENSLOW A, Switalska M, Nowak M, Maciejewska M, et al
    The effects of 1,4-dimethylpyridine in metastatic prostate cancer in mice.
    BMC Cancer. 2017;17:177.
    PubMed     Text format     Abstract available

  5. CHEN L, Wolff DW, Xie Y, Lin MF, et al
    Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5.
    BMC Cancer. 2017;17:179.
    PubMed     Text format     Abstract available


    Br J Cancer

  6. LIN HM, Mahon KL, Spielman C, Gurney H, et al
    Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.
    Br J Cancer. 2017 Mar 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Br J Radiol

  7. YU J, Fulcher AS, Winks SG, Turner MA, et al
    Diagnosis of Typical and Atypical Transitional Zone Prostate Cancer and its Mimics at Multiparametric Prostate MRI.
    Br J Radiol. 2017 Mar 3:20160693. doi: 10.1259/bjr.20160693.
    PubMed     Text format     Abstract available


    Cancer

  8. RADHAKRISHNAN A, Grande D, Mitra N, Bekelman J, et al
    Second opinions from urologists for prostate cancer: Who gets them, why, and their link to treatment.
    Cancer. 2017;123:1027-1034.
    PubMed     Text format     Abstract available


    Cancer Lett

  9. EL BEZAWY R, Cominetti D, Fenderico N, Zuco V, et al
    miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis.
    Cancer Lett. 2017 Mar 5. pii: S0304-3835(17)30150.
    PubMed     Text format     Abstract available


    Clin Imaging

  10. ZATTONI F, Agostini E, Cattaneo F, Maruzzo M, et al
    Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
    Clin Imaging. 2017;43:110-116.
    PubMed     Text format     Abstract available


    Eur Radiol

  11. VAN DEN BOS W, de Bruin DM, van Randen A, Engelbrecht MR, et al
    MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.
    Eur Radiol. 2016;26:2252-60.
    PubMed     Text format     Abstract available


    Eur Urol

  12. ANNALA M, Struss WJ, Warner EW, Beja K, et al
    Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    Eur Urol. 2017 Mar 1. pii: S0302-2838(17)30112.
    PubMed     Text format     Abstract available

  13. REIG O, Marin-Aguilera M, Carrera G, Jimenez N, et al
    Corrigendum re: "TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer" [Eur Urol 2016;70:709-13].
    Eur Urol. 2017 Mar 1. pii: S0302-2838(17)30116.
    PubMed     Text format    

  14. VENDERINK W, van Luijtelaar A, Bomers JG, van der Leest M, et al
    Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.
    Eur Urol. 2017 Feb 28. pii: S0302-2838(17)30110.
    PubMed     Text format     Abstract available


    Int J Oncol

  15. LI W, Li Y, Li G, Zhou Z, et al
    Ectopic expression of the ATP synthase beta subunit on the membrane of PC-3M cells supports its potential role in prostate cancer metastasis.
    Int J Oncol. 2017 Feb 16. doi: 10.3892/ijo.2017.3878.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  16. MORRIS WJ, Tyldesley S, Rodda S, Halperin R, et al
    Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boo
    Int J Radiat Oncol Biol Phys. 2016 Nov 24. pii: S0360-3016(16)33484.
    PubMed     Text format     Abstract available


    Invest Radiol

  17. SMEENGE M, Tranquart F, Mannaerts CK, de Reijke TM, et al
    First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study.
    Invest Radiol. 2017 Mar 2. doi: 10.1097/RLI.0000000000000362.
    PubMed     Text format     Abstract available


    J Natl Med Assoc

  18. VERGES DP, Dani H, Sterling WA, Weedon J, et al
    The Relationship of Baseline Prostate Specific Antigen and Risk of Future Prostate Cancer and Its Variance by Race.
    J Natl Med Assoc. 2017;109:49-54.
    PubMed     Text format     Abstract available


    Lancet Oncol

  19. BRATT O, Hugosson J, Klotz L, Gnanapragasam V, et al
    The drama of prostate cancer diagnostics.
    Lancet Oncol. 2017;18:e132.
    PubMed     Text format    

  20. IVERSEN P, Roder MA, Klemann N
    The drama of prostate cancer diagnostics - Authors' reply.
    Lancet Oncol. 2017;18:e133.
    PubMed     Text format    


    N Engl J Med

  21. HONG TS, Allen JN, Shellito PC
    Case 39-2016: A Man with a History of Prostate Cancer and Recent Rectal Bleeding.
    N Engl J Med. 2017;376:898.
    PubMed     Text format    


    Nat Rev Urol

  22. STONE L
    Prostate cancer: Targeting metabolism.
    Nat Rev Urol. 2017 Mar 7. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    Oncol Rep

  23. YU H, Sun SQ, Gu XB, Wang W, et al
    Atorvastatin prolongs the lifespan of radiationinduced reactive oxygen species in PC-3 prostate cancer cells to enhance the cell killing effect.
    Oncol Rep. 2017 Feb 14. doi: 10.3892/or.2017.5447.
    PubMed     Text format     Abstract available


    Prog Urol

  24. LEON P, Cancel-Tassin G, Koutlidis N, Calves J, et al
    [Prevalence and diversity of management of prostate cancer patients classified as low risk using D'Amico group or Cancer of the Prostate Risk Assessment (CAPRA) score: A French multicenter study].
    Prog Urol. 2017 Feb 28. pii: S1166-7087(17)30017.
    PubMed     Text format     Abstract available


    Prostate

  25. KHAN S, Cai J, Nielsen ME, Troester MA, et al
    The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC.
    Prostate. 2017 Mar 6. doi: 10.1002/pros.23342.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: